⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NKTR News
Nektar Therapeutics
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR
globenewswire.com
NKTR
Pomerantz LLP Launches Class Action Litigation Against Nektar Therapeutics – NKTR
accessnewswire.com
NKTR
Holzer & Holzer, LLC Reminds Investors of Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Aquestive Therapeutics, Inc. (AQST), Nektar Therapeutics (NKTR), and Eos Energy Enterprises, Inc. (EOSE)
globenewswire.com
AQST
NKTR
EOSE
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misleading Institutional Shareholders: Levi & Korsinsky
globenewswire.com
NKTR
Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight
globenewswire.com
BIIB
VRTX
AZN
VTRS
NKTR
CLMB
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
globenewswire.com
NKTR
NKTR DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026 Ready to Announce with Confidence?
newsfilecorp.com
NKTR
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
prnewswire.com
NKTR
NKTR Shareholders Have Opportunity to Lead Nektar Therapeutics Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
accessnewswire.com
NKTR
Pomerantz LLP Moves Forward with Class Action Litigation Against Nektar Therapeutics – NKTR
accessnewswire.com
NKTR